Skip to content
value.today
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST
$10 Mmarket cap on Oct 27, 2026-88.5% since Jan 2024
Compare
World rank
#25,833
Revenue
—
For year ending December-2025
Net income
$-26 M
SEC filing
Employees
—

Tempest Therapeutics, Inc. in brief

Tempest Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Brisbane, California, USA. Its market value was $10 M on 27 October 2026, which makes it the 25,833rd largest listed company in the world and the 4,295th largest in the USA on this site. Matthew Angel is its chief executive. Its shares trade under the symbol TPST (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Tempest Therapeutics, Inc.

We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a portfolio of dual-targeting chimeric antigen receptor T-cells product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/B-cell maturation antigen CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma.

Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications. One of our small-molecule product candidates, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma. Amezalpat remains Phase 3-ready in HCC and we plan to pursue business development discussions to advance pivotal development. Our second small-molecule product candidate is TPST-1495, which we plan to initiate a Phase 2 study for in familial adenomatous polyposis, with first patient enrollment expected in 2026. The study is expected to be funded by the National Cancer Institute and conducted through the Cancer Prevention Clinical Trials Network, enabling advancement with limited internal capital deployment.

From the company's annual report filed with the US SEC: read the report

Tempest Therapeutics, Inc. timeline

3 events, 2012–2021
  1. 2012
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2018
  4. ✎
    Renamed Millendo Therapeutics, Inc.
    Formerly OvaScience, Inc..
  5. 2021
  6. ✎
    Renamed Tempest Therapeutics, Inc.
    Formerly Millendo Therapeutics, Inc..

Events of Tempest Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$24 M$48 M$72 M$96 M2023202420252026

World rank over time

▲ up 2,849 places since 2022
2022-01-07: #28691#28,69120222022-12-25: #28691#28,69120222023-07-30: #31089#31,08920232024-01-05: #22042#22,04220242026-03-08: #12679#12,67920262026-08-01: #22243#22,24320262026-10-13: #25163#25,16320262026-10-27: #25842#25,8422026

Rank in USA: #5,144 (Jan 2022) · #5,472 (Dec 2022) · #5,363 (Jul 2023) · #3,779 (Jan 2024) · #2,370 (Mar 2026) · #3,976 (Aug 2026) · #4,174 (Oct 2026) · #4,297 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.5×
Free cash flow yield
-262.9%
Net margin
—
Operating margin
—
Return on equity
-393.7%
Liabilities / assets
60.6%
Net debt
$-24M
Revenue growth
-53.8%
R&D / revenue
6113.3%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-27M—FY18Fiscal year ending Dec 2019: revenue —, net income $-45M—FY19Fiscal year ending Dec 2020: revenue —, net income $-19M—FY20Fiscal year ending Dec 2021: revenue —, net income $-28M—FY21Fiscal year ending Dec 2022: revenue —, net income $-36M—FY22Fiscal year ending Dec 2023: revenue —, net income $-29M—FY23Fiscal year ending Dec 2024: revenue —, net income $-42M—FY24Fiscal year ending Dec 2025: revenue —, net income $-26M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-27M$-26M—
Dec 2024——$-42M$-42M—
Dec 2023——$-29M$-29M—
Dec 2022——$-35M$-36M—
Dec 2021——$-27M$-28M—
Dec 2020——$-19M$-19M—
Dec 2019——$-45M$-45M—
Dec 2018——$-27M$-27M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-27M$0M$-27M$-6.33—
Dec 2024$-33M$0M$-33M$-19.50—
Dec 2023$-27M$0M$-28M$-1.91—
Dec 2022$-31M$1M$-32M$-3.09—
Dec 2021$-26M$0M$-26M$-7.47—
Dec 2020$-19M$0M$-19M$-41.03$0.00
Dec 2019$-41M$0M$-42M$-3.25$0.00
Dec 2018$-24M$0M$-24M$-17.58$0.00

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-14M—Dec ’24Three months to Mar 2025: revenue —, net income $-11M—Mar ’25Three months to Jun 2025: revenue —, net income $-8M—Jun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-4M—Dec ’25Three months to Mar 2026: revenue —, net income $-28M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Tempest Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-27 M
Net income
$-26 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$17 M
Total liabilities
$10 M
Total equity
$7 M

As of December-2025

Top 23 institutional investors in Tempest Therapeutics, Inc.#

As of Sep 30, 2026
23 institutions held 548,985 shares (about 2.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 2.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 23 largest institutional investors in Tempest Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC233,8880 (0.00%)1.17%$0 MNov 13, 2026
2Geode Capital Management, LLC74,076-12,549 (-14.49%)0.37%$0 MNov 6, 2026
3Vanguard Fiduciary Trust Co68,9080 (0.00%)0.34%$0 MNov 13, 2026
4BlackRock, Inc.39,0680 (0.00%)0.20%$0 MNov 13, 2026
5UBS Group AG25,170+19,534 (+346.59%)0.13%$0 MNov 10, 2026
6HRT Financial LP21,315New0.11%$0 MNov 13, 2026
7Northern Trust Corp20,1360 (0.00%)0.10%$0 MNov 16, 2026
8Citigroup Inc15,426New0.08%$0 MNov 4, 2026
9StoneX Group Inc.13,668New0.07%$0 MNov 3, 2026
10Vanguard Personalized Indexing Management, LLC11,672New0.06%$0 MNov 16, 2026
11TRB Wealth Management, LLC10,846New0.05%$0 MNov 16, 2026
12Nuveen, LLC5,958New0.03%$0 MNov 10, 2026
13Tower Research Capital LLC (TRC)4,846+924 (+23.56%)0.02%$0 MNov 16, 2026
14Morgan Stanley2,0220 (0.00%)0.01%$0 MNov 13, 2026
15Osaic Holdings, Inc.1,439-74 (-4.89%)0.01%$0 MNov 12, 2026
16Federation des caisses Desjardins du Quebec2920 (0.00%)0.00%$0 MNov 16, 2026
17Northwestern Mutual Wealth Management Co134New0.00%$0 MNov 13, 2026
18SBI Securities Co., Ltd.560 (0.00%)0.00%$0 MOct 22, 2026
19Royal Bank Of Canada280 (0.00%)0.00%$0 MNov 16, 2026
20Parallel Advisors, LLC180 (0.00%)0.00%$0 MNov 3, 2026
21FMR LLC15New0.00%$0 MNov 10, 2026
22BNP Paribas Financial Markets30 (0.00%)0.00%$0 MNov 12, 2026
23Caitong International Asset Management Co., Ltd1-2 (-66.67%)0.00%$0 MOct 29, 2026

Mutual funds holding Tempest Therapeutics, Inc.#

5 funds hold shares worth $0 M. Since their previous reports 5 added shares and 2 sold, buying $0 M net.
Mutual funds holding Tempest Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.128,944$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.104,944$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC50,985$0 M—<0.01%+110%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC15,677$0 M—<0.01%+255%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,495$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC24,406$0 M—<0.01%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,495$0 M—<0.01%newMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC4,421$0 M—<0.01%newMay 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.35,200$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.104,944$0 M—<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Tempest Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1.0 M
2 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$1.0 M
open market only
Insiders on file
33
since
$1.0 M-$967 K$0Jun 2024: bought $16 K (1 trades), sold $0 (0 trades)Jun 24Jul 2024: bought $84 K (2 trades), sold $0 (0 trades)JulAug 2024: bought $0 (0 trades), sold $967 K (2 trades)AugMar 2026: bought $1.0 M (2 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Tempest Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Matthew AngelCEO and President, Director, 10% ownerBuyindirect+231,482$2.160$500 K231,482Form 4
filed Matthew AngelCEO and President, Director, 10% ownerBuyindirect+231,482$2.160$500 K231,482Form 4
filed Versant Venture Capital VI, L.P.10% ownerSell-387,999$1.100$427 K209,941Form 4
filed Versant Venture Capital VI, L.P.10% ownerSell-400,000$1.350$540 K597,940Form 4
filed Stephen R. BradyPresident and CEO, DirectorBuy+35,000$2.110$74 K46,376Form 4
filed Samuel WhitingChief Medical OfficerBuy+4,672$2.130$10 K9,573Form 4
filed Justin TrojanowskiCorporate ControllerBuy+7,500$2.160$16 K22,168Form 4
filed Thomas WoiwodeDirector, 10% ownerBuyindirect+2.12 M$2.360$5.0 M2.12 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Tempest Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
241,168
4.9% of shares · 1.88 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 2.023-for-1 split

Trading halts

  • 2025-11-19 15:05 UTC, code LUDP, resumed 15:10 UTC
  • 2025-11-19 14:53 UTC, code LUDP, resumed 14:58 UTC
  • 2025-11-19 14:41 UTC, code LUDP, resumed 14:51 UTC
  • 2025-04-08 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 2,222 shares at $0.51
  • : 701 shares at $0.62
  • : 8,345 shares at $0.74
  • : 14 shares at $0.79
  • : 142 shares at $0.81

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Tempest Therapeutics, Inc. scorecard#

Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 27, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-6.33 vs -19.50Diluted EPS -6.33 in fiscal 2025 against -19.50 the year before (report's currency).
    • ✗Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$19 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-203.6%-203.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.50 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year93.4%Diluted shares up 93.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Tempest Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Tempest Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue————————0.30.7
Cost of revenue————————0.85.4
Research and development132817231714r28141822
Selling, general and administrative————————2849
General and administrative141412129.84.9r188.76.0—
Operating expenses————————5182
Operating income−27−42−29−35−27−19r−45−27−84r−81
Interest expense and finance costs0.21.31.41.61.30—0.10.3—
Share of profit of associates————————−1.0−1.5
Other non-operating income (expense)0.30.2−0.3−1.1−1.30.1——−0.0−0.2
Income before tax————————−51−82
Income tax000000——0.10.2
Net income including minority interests−26−42−29−36−28−19r−45−27−85—
Minority interests' share of net income——————00.0−0.0—
Net income attributable to shareholders−26−42−29−36−28−19r−45−27−85r−82
Earnings per share, basic-6.33-19.50r-1.91-3.09-7.47-41.03r-3.25-17.58-321.81r-2.56
Earnings per share, diluted-6.33-19.50r-1.91-3.09-7.47-41.03r-3.25-17.58-321.81r-2.56
Shares, weighted average (basic)4.12.1r15123.80.5————
Shares, weighted average (diluted)4.12.1r15123.80.5r141.50.3r32
Dividends per share—————0.000.000.00——
Balance sheet
Cash and cash equivalents7.73039315219r627318r44
Short-term investments———————05270
Other current assets0.40.50.10.30.60.1r6.33.41.1r2.1
Current assets8.33140336920r718320r116
Property, plant and equipment0.60.90.81.11.11.1——3.15.6
Right-of-use (leased) assets7.58.610.0123.11.9r3.3———
Investments in associates————————0.10.1
Total assets174152467323r758420r123
Accounts payable1.02.50.81.11.01.1r1.52.01.3r2.2
Debt due within a year06.44.3——0.20.20.20.2—
Current liabilities3.3149.47.3203.2r139.84.1r13
Long-term debt—06.310150r0.20.40.6—
Lease liabilities (non-current)6.98.19.2102.01.7r2.4———
Total liabilities10222528374.9r15114.8r14
Retained earnings−233−207−165−136−100−72r−209−164−137r−250
Shareholders' equity6.719271836−69r−50r71−131r108
Minority interests—————0.71.32.22.2—
Total equity6.719271836−69r6073−129−51
Total liabilities and equity174152467323r758420r123
Shares outstanding4.93.4r22116.90.5r18130.2r36
Cash-flow statement
Depreciation and amortization————————1.72.2
Share-based compensation3.15.32.51.61.10.5r4.31.46.99.2
Cash from operating activities−27−33−27−31−26−19r−41−24−20r−62
Capital expenditure0−0.4−0.2−0.6−0.1−0.1r−0.4−0.0−0.0r−2.6
Acquisitions, net of cash acquired——————0−0.5−0.5—
Cash from investing activities0−0.4−0.2−0.6−0.1−0.0r4.01.90.5r8.3
Debt issued————150——6.0—
Debt repaid−6.4−4.4—−4.7—−0.1−0.2−0.2−10—
Shares issued6.029368.9330r270054
Cash from financing activities4.32536115935r2778−4.5r54
Exchange-rate effect on cash—————0.20.00.10.0—
Change in cash—————−25−1056−24—
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Tempest Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.3 M
Mr. Brady
Other top executives, average
$1.0 M
the CEO earned 2.2× this
$100 invested is now
$19
Tempest Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Brady$2.3 M$1.5 M$1.0 M$19
2024Mr. Brady$1.9 M−$1.7 M$842 K$16
2023Mr. Brady$7.0 M$4.4 M$2.4 M$83

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Tempest Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 9 · Material agreement 8 · Unregistered share sale 5 · Shareholder rights changed 1 · Shareholder vote 7 · Results announced 3

Tempest Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Delisting notice8-K
Directors and officers8-K
Shareholder vote8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K
Material agreement8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Change in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share sale8-K
Directors and officersShareholder rights changedShareholder vote8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Tempest Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2026$8 MPrivate placement after listing$2 to $10 million1optionsSEC
May 2026$4 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Mar 2026$2 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Apr 2022$15 MPrivate placement after listing$10 to $50 million2equity, optionsSEC
Mar 2013$35 MNo. 3$10 to $50 million31equitySEC
Jun 2012$5 MNo. 2$2 to $10 million253equitySEC
Mar 2012$37 MNo. 1$10 to $50 million19equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Tempest Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
26
2016–2025
Latest
26 people
2025-04-17
Tempest Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025···26········26
2021············—
2020············—
2018············—
2017············—
Tempest Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
26 peopleRestructuring planSEC 8-K“As part of the plan, the Company will reduce its workforce by 21 of 26 full-time employees, effective April 30, 2025.”Filing
85% of workforceRestructuring planSEC 8-K“In connection with the Plan, the Company plans to reduce its workforce by up to 85%, with the majority of the reduction in personnel expected to be completed by April 15, 2021.”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling
70% of workforceRestructuring planSEC 8-K“In connection with the restructuring plan, the Company plans to reduce its workforce by approximately 70%, with the majority of the reduction in personnel expected to be completed …”Filing
50% of workforceRestructuring planSEC 8-K“(“OvaScience” or the “Company”) announced that it will restructure its organization to reduce its workforce by approximately 50% in connection with its determination that its strat…”Filing
50% of workforceRestructuring planSEC 8-K“(“OvaScience” or the “Company”) announced that it (i) continues to be focused on advancing its two potentially transformative fertility treatments, OvaTure SM , in preclinical deve…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Tempest Therapeutics, Inc. compares in Biotechnology

  • Market cap$10 M · higher than 11% of 726
  • Revenue growth-53.9% · higher than 16% of 438
  • Price / book1.5× · lower than 66% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Tempest Therapeutics, Inc.🇺🇸$10 M——-53.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 27, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Tempest Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Tempest Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Tempest Therapeutics, Inc.? Suggest a correction